# Newton Fund

> Newton Fund is a VC fund in San Francisco backing Software and Medical. See 20 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 20
- Last investment: Jul 2021
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.newtonfund.vc/

Newton Fund is a VC fund in San Francisco focused on Software and Medical. Early Stage DeepTech VC Fund

## Contacts

5 contacts available for Newton Fund. Shizune tracks 4 team members at Newton Fund. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/newton-fund?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Software | 9 | 45% |
| Medical | 5 | 25% |
| Health Care | 5 | 25% |
| 3D Technology | 3 | 15% |
| Biotechnology | 3 | 15% |

42 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 15 | 75% |
| Venture - Series Unknown | 2 | 10% |
| Pre-Seed | 1 | 5% |
| Series A | 1 | 5% |
| Series B | 1 | 5% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 17 | 85% |
| Canada | 2 | 10% |
| Singapore | 1 | 5% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Andy Reed | Director | 0 | https://shizune.co/investors/profile/andy-reed |
| Lisheng Wang | Managing Partner | 7 | https://shizune.co/investors/profile/lisheng-wang |
| Mark Zhu | Partner | 0 | https://shizune.co/investors/profile/mark-zhu-a985 |
| Swati Chaturvedi | General Partner | 0 | https://shizune.co/investors/profile/swati-chaturvedi-2 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Genomelink | Genomelink is a platform where people discover more with their DNA data and help businesses build, market and do research with it. The best founders in consumer genomics with real experience in the industry for many years, including M3, Inc. ($13B valued Meditech in Japan), a founding member of the Japanese version of 23andMe, and leadbioinformatician and software engineer at a joint-venture between Illumina and Sony. Raised $4M for Seed Round from Berkeley SkyDeck, SONY, and top-tier Japanese VCs. Supported by Illumina Accelerator, Carlos Bustamante Lab at Stanford University among others. | $3.5M | Seed | Jul 01, 2021 |  |
| Rellevate | Rellevate is a financial services company dedicated to empowering consumers through innovative services that allow consumers to access, move and use their money anytime, anywhere. Rellevate's products, offered primarily via employers, include a Digital Account with interest with Pay Any-Day, Bill Pay, and Send Money.Rellevate is focused onhelping employers improve employee retention, reduce turnover, boost satisfaction, and loyalty by enabling empowering consumers to take greater control over their finances via its product suite. | $1.3M | Seed | Apr 01, 2021 |  |
| Bambu | Bambu is a leading global digital wealth technology provider for financial institutions. We enable companies to make saving and investing simple and intelligent for their clients. The cloud-based platform is powered by our proprietary algorithms and machine learning tools. The company serves over 20 financial institutions globally. Founded in 2016,Bambu is headquartered in Singapore with a subsidiary in the United Kingdom and the United States and EMEA representatives. |  | Series B | Mar 15, 2021 |  |
| Mesentech | Mesentech is a company focused on treating diseases and medical conditions that relate to bone. They are generating a series of products, from different, but complementary approaches that will effectively address currently difficult to treat conditions.Bone can be one of the most difficult organs to access and treat with medicines. It’s hardsurface and low porosity presents challenges in adequately getting drugs to either the bone surface or to its interior. Treatment often requires administering high doses of a drug over extended periods. Not only is achievement of efficacy compromised, but also side- effects may be more prevalent and can limit treatment effectiveness.Mesentech’s lead technology is a proprietary bone targeting system that can effectively deliver small-molecule and biological drugs to the surface or to the interior of bone. Pre-clinical in-vivo models have confirmed the utility of this technology. |  | Seed | Feb 01, 2021 |  |
| WRM Software | WRM Software develops business productivity applications focused on improving business processes. WRM's storm manager and ops manager applications are designed to be easy-to-use and connect field and office operations seamlessly. It ensures everyone to have access to the latest information at all times. |  | Seed | Dec 10, 2020 |  |
| BRELYON | Brelyon is a developer of a display used to replace traditional monitors and virtual reality headgears. It was founded in 2019 and is headquartered in San Mateo, California. | $1.6M | Pre-Seed | Jul 15, 2020 |  |
| Avails Medical | Rapid digital detection of infections and treatment optimization. Accurate, rapid, digital detection of infections in any bodily fluid to indicate in real-time which drugs will be most effective at the point-of-prescription.Today the US spends $20B+ on infection detection. The market for efficient bacteria resistance detection has enormouspotential. Avails Medical is pioneering the current diagnostics market with a groundbreaking technology that targets this global health threat. Avails Medicals' cost-effective platform will transform the diagnostics market by enabling for the first time diagnostic-guided therapy at the point-of-care, reducing time-to-treatment from days to minutes. |  | Venture - Series Unknown | Mar 24, 2020 |  |
| ProteoWise | ProteoWise’s technology provides a unique combination of high information content, high throughput, and low cost - all while simplifying the western blot dramatically. This combination is what’s driving the genomic revolution and is needed for proteomics.ProteoWise is founded by a seasoned team of scientists from the Strittmatter Lab at YaleUniversity with a history of innovation. | $6.3M | Venture - Series Unknown | Mar 23, 2020 |  |
| Skycool Systems | At SkyCool Systems, our mission is to deliver sustainable, energy-efficient cooling solutions to customers interested in reducing energy costs and carbon footprint. We’ve pioneered radiative cooling as a technology, and shown that specially designed optical films can enable this passive approach to cooling throughout the day. These optical filmsare highly reflective to sunlight but also emit thermal radiation exceptionally well to the cold of space through our atmosphere, enabling daytime operation during the hottest hours of the day. Our core innovation is a rooftop cooling panel. We apply the radiative film to rooftop panels and integrate them with air conditioning and refrigeration systems. The panels can be used as an add-on to air conditioning and refrigeration systems and in some circumstances even replace an air condensing unit. Our technology is accelerating the transition to a cleaner and more sustainable future. | $1.7M | Seed | Jan 31, 2019 |  |
| ProbiusDx | ProbiusDx is an electronic sensing company that provides a diagnostic technology for detecting and monitoring blood concentrations. | $2.7M | Seed | Oct 26, 2018 |  |

10 of 20 investments shown.

## Co-investors
- [Propel(X)](https://shizune.co/investors/profile/propelx) — VC Fund, 19 deals together
- [Liquid 2 Ventures](https://shizune.co/investors/profile/liquid2-ventures) — VC Fund, 3 deals together
- [Connecticut Innovations](https://shizune.co/investors/profile/connecticut-innovations) — VC Fund, 2 deals together
- [SAV (Scale Asia Ventures)](https://shizune.co/investors/profile/scale-asia-ventures) — VC Fund, 2 deals together
- [Amity Ventures](https://shizune.co/investors/profile/amity-ventures) — VC Fund, 1 deal together
- [Anorak Ventures](https://shizune.co/investors/profile/anorak-ventures-2) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Newton Fund invest in?

Newton Fund invests primarily in Software, Medical and Health Care startups, most often at Seed and Venture - Series Unknown stage. Most of the 20 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Newton Fund?

Public channels for Newton Fund include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Newton Fund?

The team at Newton Fund includes Andy Reed (Director), Lisheng Wang (Managing Partner) and Mark Zhu (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co